Patients who switched between 2 different biosimilar infliximab products during treatment of chronic plaque psoriasis did not experience adverse events or change in severity . In the study, 24 patients with psoriasis (12 of whom also had psoriatic arthritis) were switched from one infliximab biosimilar, CT-P13, to another, SB2. The patients, who had a previous exposure to CT-P13 of 23.2 (± 7.51) months, were then followed for 6 months after switching. Psoriasis Area and Severity Index (PASI) scores were measured at the time of the switch and at months 2, 4, and 6.
The investigators found that PASI scores at each measurement were substantially unchanged; mean scores at the time of the switch and at months 2, 4, and 6 were 0.67 (±1.38), 0.76 (±1.08), 0.71 (±0.93), and 0.42 (±0.62), respectively. In terms of adverse events (AEs), 2 infusion-related reactions, and 2 upper respiratory bacterial infections were observed in total. Despite the limited sample si...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Sustained and complete responses from the phase 3 AMAGINE-2 and -3 studies Next Article
ABP501 biosimilar for adalimumab: What you need to know »
Table of Contents: SPIN 2019
Aetiology: Triggers and Risk Factors
Advances in Therapy
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.